ACXP · Acurx Pharmaceuticals, Inc.

preparados farmaceuticos · CIK 0001736243

Acurx Pharmaceuticals, Inc. (ACXP) cotiza en el NASDAQ y se dedica a preparados farmaceuticos. Aqui estan 1 documento que ha presentado ante la SEC, desde 13 ago 2026. En sus informes aparecen frases que este sitio vigila: duda sustancial sobre la continuidad de la empresa, aviso de incumplimiento de las reglas de cotizacion, contrasplit de acciones y programa de venta continua de acciones (atm). Estan citadas literalmente mas abajo.

Documentos: 1
Ultimo: 13 ago 2026

Todavia no se publican los trimestres de caja ni la dilucion de esta empresa: hacen falta datos de sus informes que solo se recogen de las que se siguen de cerca. Lo que ves abajo son sus documentos tal y como los presento ante la SEC.

Documentos presentados ante la SEC1

2026

13 ago 202610-QInforme trimestralEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…if ever. Management plans to seek additional equity financing and grant funding, but cannot assure that such financing and funding will be available at acceptable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that the Company’s research and…
En el documentoAviso de incumplimiento de las reglas de cotizaciontexto original ▸
…business days our common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). On August 26, 2025, we received a letter from Nasdaq notifying us that we regained compliance with the Minimum Bid Price Requirement. On July 22, 2026, the Securities and Exchange Commission (“SEC”) issued an order approving Nasdaq’s new rules requiring listed companies to maintain a Market Value of Listed Securities (…
En el documentoContrasplit de accionestexto original ▸
…statements are read in conjunction with the audited financial statements and notes thereto as of December 31, 2025 filed in the Annual Report on Form 10-K. Reverse Stock Split On August 4, 2025, the Company effected a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per Share. All issued and outstanding common…
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…C Warrants to purchase 66,667 shares of common stock and Series D Warrants to purchase 66,667 shares of common stock for gross proceeds of approximately $4.0 million. On November 15, 2023, the Company entered into a Sales Agreement and established an “At-the-Market” offering (the “ATM Program”), pursuant to which the Company may offer and sell, from time to time through A.G.P/Alliance Global Partners, as sales agent, shares of its common stock having an aggregate offering…